genomics is changing everything

Genomics is changing everything.

Genomics is changing everything.

Genomics offers a set of revolutionary tools that provide insight into how all living things function and interact with their environment. By studying the genetic material (or blueprint) of organisms, we can understand how they work, and find out what happens when genes interact with each other and with the environment. Genomics has given us the ability to better understand and treat disease, produce more nutritious food, solve global challenges such as malnutrition and water safety, and tackle industrial waste for a cleaner world.

The Ontario Genomics Institute (OGI) is leading the way in genomics research in Ontario. As a driver and catalyst of our province’s life sciences industry, OGI identifies, attracts and supports investment in Ontario-led research, and facilitates genomics research translation and technology development. OGI’s portfolio includes nearly 100 companies and genomics research projects

representing more than $850 million in research and commercialization investment.

Scintelligence, a division of the Ontario Genomics Institute, helps industry tap into the potential of life science solutions. This team of life science and business development experts identifies needs, connects companies to world-class researchers, and helps secure funding for research and development in industries such as health, agriculture, mining, cleantech, and water.

Genomics is changing everything – and this is only the beginning. The cost of sequencing a human genome – the three billion bases of DNA in a set of human chromosomes – dropped from $3 billion in 2003 to $1,000 in 2014, while the power of the technology increased by 100 million. Faster, cheaper genome sequencing is providing new insights into every aspect of life on earth.

2

Personalized medicine is an emerging practice that uses people’s unique genetic and environmental information to tailor health care decisions to their specific needs. Genetic screening delivers precise diagnoses, increases our ability to develop drugs targeted to individual genetic profiles, and helps physicians select the best medication and dosage for each person.

Genomics is changing health care.

A key aspect of cancer is caused by small changes in the genetic code, which cause cells to divide and grow differently than normal cells. A better understanding of the genetic changes in cancer cells is leading to more effective diagnosis and treatment, tailored to the genetic profile of each patient’s cancer.

For example, with breast cancer, molecular and genetic tests can help determine the best treatment for each patient. Women with certain variants in the BRCA genes have an 80% chance of developing breast cancer, and a genetic test can guide preventative measures.

Approximately 30% of women with breast cancer are positive for the HER2 gene, which causes aggressive growth in tumour cells. These women can receive a targeted therapeutic called Herceptin, which reduces the recurrence of tumours by 52%.

Although half of all breast cancer patients receive chemotherapy, it extends the life of less than a quarter of patients. Quickly determining which women are not responding allows them to be switched to other treatments earlier, avoiding harmful side effects and improving outcomes.

Improving cancer survival rates

5

6

Helping doctors prescribe the right drugs for mental illness Mental illnesses are the result of a complex interaction between genetic and environmental factors, affecting about 20% of Canadians. However, many prescribed drugs are only effective about half the time, so finding the right medication becomes a matter of trial and error. Serious side effects are a major issue.

Genetic testing identifies patients who will not respond to medications or will experience side

effects, helping physicians prescribe the appropriate drugs, maximizing the benefits for each patient and decreasing the risk of side effects. Giving patients the right medication earlier can reduce the burden of mental illness for patients and their families, and save the health care system money by reducing ineffective treatments.

7

Identifying rare childhood diseasesOver 80% of the more than 7,000 known rare conditions have a genetic basis, with 75% presenting during childhood. Gene mutations cause thousands of rare diseases, including conditions such as muscular dystrophy and cystic fibrosis. While individually rare, these disorders are collectively common, affecting one in 12 people worldwide.

One-third of Canadians who have a rare disease are diagnosed incorrectly. Through the use of powerful new gene sequencing technologies, however, one new disease gene is being discovered each week, families

are receiving the correct diagnoses, and researchers are gaining new insight into genetic causes and potential new treatments. A correct diagnosis ends the diagnostic odyssey for families and helps children get available treatments earlier, allowing them to avoid invasive procedures and ineffective treatments. Plus, identifying the genetic cause of disease can open the door to finding new treatments – pharmaceutical partners are testing drugs already approved for common diseases to identify possible therapies.

People living in developing and underprivileged nations face significant challenges including malnutrition, high rates of infectious disease, and limited access to safe water. Genomics is finding practical solutions to poverty-related problems, providing high-nutrient foods to fight hunger and malnutrition, enhanced disease diagnosis technologies to identify and treat illness early, and tools to ensure clean water supply.

Genomics is changing the developing world.

Hundreds of thousands of children in the developing world die needlessly every year. One simple solution can help save them: a variety of fortified rice that produces vitamin A, a nutrient that is essential for growth and development, and for maintaining a healthy immune system.

Deficiency in dietary vitamin A kills an estimated 670,000 children under the age of five each year, and is the most common cause of blindness in children worldwide. Those who do not have enough vitamin A in their diet are less able to fight infection and are therefore more likely to die from disease.

Created to combat that deficiency, golden rice is a variety of rice that has been modified to produce beta carotene, making it more nutritious and turning it a golden colour. Fifty grams of golden rice provides 60% of the recommended daily intake of vitamin A.

Three billion people worldwide depend on rice as their staple food. Growing golden rice is far more cost-effective than providing vitamin supplements and is more likely to be adopted by communities where rice is a staple. Unfortunately, golden rice has met with significant opposition from environmental and anti-globalization activists.

Lowering child mortality with golden rice

9

In developing countries where medical facilities are few and far between, fast, accurate, convenient and inexpensive testing is essential to providing effective patient care and preventing the spread of infection. However, many of the tests routinely administered in well-equipped medical facilities are unsuitable for use in the developing world.

Thanks to genomics research, new point-of-care technologies that detect diseases such as malaria,

AIDS and hepatitis C could give people in developing nations access to fast, accurate and potentially life-saving diagnoses. Rapid tests capable of detecting diseases in a single patient visit are playing an enormous role in combating disease. On-demand molecular testing empowers clinicians to diagnose patients quickly, make timely treatment decisions, avoid wasting precious resources on ineffective treatments, and help stop the spread of infection.

10

Improving health outcomes with point-of-care diagnostics

Water contaminants can lead to debilitating and deadly diseases such as dengue fever, cholera, dysentery, and diarrhea. More than a billion people worldwide have no access to a decent water supply. As a result, unsafe water, poor sanitation and hygiene are the leading causes of death in the developing world. In fact, the majority of illnesses in developing countries are caused by poor water and sanitation conditions.

DNA-based technologies can quickly and accurately detect pathogens in a water supply, identifying unsafe water before it can make people sick. These versatile technologies can be adapted to identify a variety of contaminants, and are suitable for the unique conditions of developing countries.

Identifying unsafe water supplies

11

For centuries, humans have been genetically enhancing plants and animals by selectively breeding for desirable physical qualities such as size, colour, or yield. Using DNA sequencing technologies, we can quickly and effectively choose the best characteristics, allowing us to increase yields, produce more nutritious foods, decrease susceptibility to drought and disease, improve profitability for farmers, and ensure the safety of our food.

Genomics is changing agriculture.

New approaches to plant improvement are creating higher quality food in greater quantities, helping meet the world’s growing demand, and increasing profitability for farmers. Using a technology called reverse mutagenesis, which allows scientists to induce genetic changes in seeds, plant breeders are speeding up naturally occurring processes, and creating plants that have beneficial traits such as disease or pest resistance, improved flavour, enhanced colour, higher yield, and drought resistance.

These plant breeding techniques increase the sustainability of agriculture. Improving drought resistance and creating higher yield crops decreases agricultural water use, and disease-resistant crops decrease the need for pesticides. Ultimately, these technologies result in fewer plant deaths and better quality products for increased profitability for farmers and growers.

Growing stronger plants

13

An increased understanding of the genetic traits of animals has improved milk quality and animal health significantly. Sequencing technologies have revolutionized breeding in the dairy industry by providing an affordable and effective way to determine which animals have the best genetic traits, and identify the negative traits that should be minimized.

Traditional breeding techniques use pedigree information, which predicts the fitness of a cow with about 30% accuracy. Not only is genetic testing more dependable

(it has a 70% accuracy rate), it significantly reduces the time needed to identify high-value animals. Genomic tests can be used at an early age to test bulls before they produce sperm and cows before they produce milk.

Similar technologies are improving animal welfare by identifying the genes associated with hoof health, the leading cause of dairy cattle lameness. Improving hoof health results in fewer culled cows, lower milk production loss, increased reproductive success, and lower treatment costs.

Breeding healthier animals

14

Agricultural production has been threatened due to a significant decline in honeybees, which pollinate about 75% of major global crops. Identifying genetic traits that improve pest resistance in honeybees could address the issue of colony collapse disorder, a serious problem threatening the health of honeybees and the economic stability of commercial beekeeping and pollination operations worldwide.

One of the largest causes of global honeybee population decline is the Varroa mite, a parasite that weakens

honeybees and carries infection. The effect of this parasite can be minimized though hygienic behavior, which is a genetic trait that allows a bee colony to eliminate infected bees and prevent the spread of mites.

By selectively breeding bees for improved hygienic behavior, we can increase their natural resistance to Varroa mites. And by improving colony hygiene, beekeepers can avoid chemical treatments, which can result in residue being left behind in the honey and wax, and lead to chemical-resistant pathogens.

Helping save the honey bees

15

Microbes that have adapted to living in toxic environments are frequently able to clean up contamination from oil spills and industrial waste. Using metagenomics, the study of microbial organisms in their natural environments, we can gain insight into how these organisms function. This in-depth understanding of microbial communities presents an incredible opportunity to develop new environmental solutions, increase sustainability, and create a cleaner world.

Genomics is changing the way industry impacts the environment.

Microbes and enzymes may become critical to increasing yield and decreasing toxic tailings in the mining industry. Mine tailings contain various ores and materials contaminated by arsenic and other substances that are poisonous to humans and animals, and harmful to the environment. Using genomics, we can understand and harness the power of existing microbes to clean up mine tailings and recover high-value products from waste.

Bioleaching extracts minerals using microorganisms, augmenting traditional processes and reducing the

need for extreme heat or chemicals. These naturally occurring bacteria are harmless to humans and the environment, but thrive in the toxic conditions present in mine tailings.

Microbial communities can also be optimized to clean up contaminated sites and address industry challenges such as acid mine drainage. Using bacteria to leach metals or minerals from mine tailings can extract value from low-grade ores and waste products, improving profitability while remediating waste products, and reducing operating costs.

Cleaning up mine tailings

17

Measuring the environmental impact of industry and society is essential to long-term sustainability. Biomonitoring looks at the DNA contained in environmental samples to measure the types and quantities of organisms living in a given environment.

Biomonitoring provides a fast, accurate, and cost-effective way to look at large numbers of organisms and communities. This technology can be used as a biological early-warning system, telling us when environmental

stresses are reaching a critical point. They can also be used to measure biological diversity, look for changes over time, identify potential remediation techniques, and assess environmental clean-up initiatives.

Biomonitoring helps industries that require environmental monitoring, such as the mining and energy sectors, by providing improved strategies for assessing the impact of pollutants on ecosystems, and for cleaning up contaminated environments.

Measuring biodiversity

18

Mining, manufacturing, agriculture, food production, and the pulp and paper industries all produce wastewater that is hazardous to the environment, expensive to clean up and poses a health hazard for people in both developed and developing countries.

Bioremediation is a waste management technique that uses organisms to remove or neutralize pollutants

from a contaminated site. Microbial metagenomics is being used to identify water contaminants, and determine which bacteria or organisms can safely and effectively clean up waste. These microbes are being harnessed and optimized through commercial microbial communities or bioreactors.

Cleaning up wastewater

19

DVS Sciences Inc. developed a revolutionary technology, the mass cytometer for single cell analysis. In February 2014, Fluidigm acquired the company for $207 million, and the wholly owned subsidiary, Fluidigm Canada, will continue manufacturing and research in their Ontario facilities.

ArcticDX Inc. is a molecular diagnostic company working in the areas of colorectal cancer and age-related macular degeneration. The company currently employs 30 people and generated more than $8 million in revenue in 2013.

Xagenic Inc. has developed a revolutionary class of molecular diagnostic chips that enable inexpensive, on-demand, point-of-care diagnosis. They completed Series A funding of $10 million in January 2012 and closed an additional round of $20 million in November 2013.

FIO Corporation has created a mobile point-of-care device for infectious disease diagnosis and information management by combining smartphone technology, biotechnology, and nanotechnology. The company has raised more than $40 million and their products are being used at 200 sites in 12 developing countries.

Rna Diagnostics is an early stage diagnostics company developing RNA based assays aimed at assisting in the management of cancer chemotherapy. Rna Diagnostics has raised over $2.5 million in private investment. They currently employ 10 people and are expected to scale to over 50 employees in the next five years.

Encycle Therapeutics is a Toronto-based company developing an emerging class of therapeutics called macrocycles. They have partnered with MaRS Innovation and CQDM, a Quebec-based pre-competitive research consortium and a Centre of Excellence for Commercialization and Research.

Business Development

20

The Ontario Genomics Institute facilitates genomics research translation and technology development. Our research programs and business development initiatives have fostered companies and helped them on their journey toward commercialization. Below are some of the companies OGI has helped.

Mining Metagenomic analysis of bioreactor systems for treating acid mine drainage.

Optimizing a microbial leach mix to recover valuable metals from tailings.

Water Pathogen detection tools to assess water quality.

Metagenomics in slow sand filtration water treatment processes.

Agriculture Genetic selection to improve milk quality and health of dairy cows.

Improving disease resistance in Ontario-grown greenhouse vegetables.

Scintelligence

21

OGI’s Scintelligence division helps industry tap into the potential of life science solutions. Scintelligence uses life science and business development expertise to identify needs, connect companies to world-class researchers, and help secure funding. Below are some of the projects we have catalyzed.

HUMAN, PLANT AND ANIMAL HEALTH

Genomics for a Competitive

Greenhouse Vegetable Industry

Keiko Yoshioka

University of Toronto

Daryl Somers

Vineland Research Innovation Centre

April 2014-March 2017

$2.4 million

SALMON and CHIPS:

Commercial Application of Genomics

to Maximize Genetic Improvement of

Farmed Atlantic Salmon on the East

Coast of Canada

Elizabeth Boulding

University of Guelph

Keng Ang

Cooke Aquaculture

April 2014-March 2017

$3.8 million

The Cancer Genome Collaboratory

Lincoln Stein


April 2014 – March 2018

$6.0 million

Applying Genomic Signal Processing

Methods to Accelerate Crop Breeding

Lewis Lukens, Cortland Griswold


July 2013 - June 2015

$0.2 million

Development of a Clinical Genomics

Informatics Infrastructure to support

Personalized Medicine*

Kathy Siminovitch

The Lunenfeld-Tanenbaum

Research Institute


$3.7 million

*This project is funded through the

Government of Ontario

Enhanced CARE for RARE Genetic

Diseases in Canada

Kym Boycott, Alex MacKenzie

Children’s Hospital of Eastern Ontario

Research Institute, Ottawa


$11.8 million

Autism Spectrum Disorders:

Genomes to Outcomes

Stephen Scherer, Peter Szatmari

The Hospital for Sick Children, Toronto


$10 million

Early Detection of Patients at High

Risk of Esophageal Adenocarcinoma

Lincoln Stein

Ontario Institute for Cancer Research,

Toronto

Tony Godfrey

Boston University (US)


$3.2 million

Research Programs

CURRENT RESEARCH PROJECTS

22

The Microbiota at the Intestinal

Mucosa-immune Interface: A

Gateway for Personalized Health

Alain Stintzi

University of Ottawa

David Mack

Children’s Hospital of Eastern Ontario,

Ottawa


$3 million

Therapeutic Opportunities to Target

Tumor Initiating Cells in Solid Tumors

Tak Mak

University Health Network, Toronto

June 2010 – May 2014

$40.0 million

Development of Highly Active Anti-

Leukemia Stem Cell Therapy (HALT)

John Dick, Jean Wang



$31.8 million

Genomics for Crop Improvement:

Agricultural Pest Management

Miodrag Grbic

Western University, London

October 2009 – March 2014

$6.3 million

Finding of Rare Disease Genes in

Canada (FORGE Canada)

Kym Boycott

Children’s Hospital of Eastern Ontario

Research Institute, Ottawa

April 2011 – June 2013

$4.1 Million

ENVIRONMENT

Biomonitoring 2.0:

A High-throughput Genomics

Approach to Comprehensive

Biological Assessment of

Environmental Change

Mehrdad Hajibabaei


July 2011 – June 2014

$3.1 million

Bioproducts and Enzymes from

Environmental Metagenomes (BEEM)

Elizabeth Edwards


David Major

Geosyntec Consultants, Guelph

October 2009 – September 2014

$11.0 million

International Barcode of Life (iBOL)

Paul Hebert


July 2008 – June 2013

$27.4 million

TECHNOLOGY DEVELOPMENT AND INFORMATICS

Development of a Low Cost

Diagnostic Platform for Infectious

Disease Testing

Shana Kelley


Graham Jack

Xagenic


$3.7 million

MedSavant: An Integrative

Framework for Clinical and Research

Analysis of Human Genomes

Michael Brudno, Gary Bader


July 2013 - June 2016

$1 million

Development of a Unified Canadian

Clinical Genomic Database

as a Community Resource for

Standardizing and Sharing Genetic

Interpretations

Jordan Lerner-Ellis

Mount Sinai Hospital, Toronto

Matthew Lebo

Brigham and Women’s Hospital (US)

July 2013 - June 2016

$1 million

23

Large Data Sets and Novel Tools for

Plant Biology for Use in International

Consolidation-Tier Data Repositories

and Portals

Nicholas Provart, Stephen Wright


July 2013 - June 2016

$1 million

ProHits Next Generation: A Flexible

System for Tracking, Analyzing and

Reporting Functional Proteomics Data

Anne-Claude Gingras

Samuel Lunenfeld Research Institute,


Mike Tyers

Institut de recherche en immunologie et

cancérologie, Université de Montréal

July 2013 - June 2015

$1 million

Leveraging Meta-transcriptomics for

Functional Interrogation of Microbiomes

John Parkinson

The Hospital for Sick Children, Toronto

July 2013 - June 2015

$0.2 million

Pathway and Network Visualization

for Personal Genomes

Lincoln Stein

Ontario Institute for Cancer Research,

Toronto

July 2013 - June 2015

$0.2 million

NorCOMM2 - In Vivo Models for

Human Disease & Drug Discovery

Colin McKerlie


Steve Brown

Medical Research Council Harwell (UK)

July 2011 – June 2014

$10.9 million

Synthetic Antibody Program:

Commercial Reagents and Novel

Therapeutics

Sachdev Sidhu, Charles Boone


July 2011 – June 2014

$9.9 million

The Centre for Applied Genomics

(TCAG)

Science & Technology

Innovation Centre

Stephen Scherer

Hospital for Sick Children, Toronto

January 2006 – September 2013

$15.6 million

Structural Genomics Consortium

(SGC) – Phase III

Aled Edwards


University of Oxford (UK)

July 2011 – December 2013

$18.7 million

2 4

HUMAN, PLANT AND ANIMAL HEALTH

Structural and Functional Annotation

of the Human Genome for

Disease Study

Robert Hegele

Robarts Research Institute, London

October 2006 – June 2011

$21.6 million

Identification of Genetic Pathways that

Regulate the Survival and Development

of Cancer and Cancer Stem Cells

Cynthia Guidos


January 2006 – March 2011

$18.7 million

Genome-Environment Interactions in

Type I Diabetes

Jayne Danska


Andrew Macpherson

McMaster University, Hamilton


$15.1 million

Autism Genome Project

Stephen Scherer



$15.6 million

Strengthening the Role of Genomics

and Global Health

Peter Singer, Abdallah Daar


April 2006 – December 2010

$10.4 million

Quantum Dot Diagnostics:

Simultaneous Genomic and Proteomic

Profiling of Multiple Pathogens at

Point-of-Care

Kevin Kain


Michael Greenberg

Fio Corporation, Toronto

January 2006 – September 2010

$9.9 million

The Dynactome: Mapping Spatio-

Temporal Dynamic Systems in Humans

Anthony Pawson, Jeff Wrana



Shawn Li


January 2006 – June 2010

$27.6 million

The Contribution of Genetic

Modulators of Disease Severity in

Cystic Fibrosis to Other Diseases with

Similarities of Clinical Phenotype

Peter Durie, Julian Zielenski



$7.6 million

Technologies for Methylome Studies

Arturas Petronis

Centre for Addiction and Mental

Health, Toronto


$0.8 million

Proteomic Technologies for the Study

of Rare Cells

Daniel Figeys

University of Ottawa


$1.5 million

International Regulome Consortium

(IRC)

Michael Rudnicki

Ottawa Health Research Institute


$23.0 million

2 5

PREVIOUSLY COMPLETED RESEARCH PROJECTS

Protein Expression Profiling Platform

for Heart Disease Biomarker Discovery

Peter Liu, Andrew Emili,

David MacLennan



$6.0 million

Assessing Risk for Colorectal

Tumours in Canada (ARCTIC)

Brent Zanke

Cancer Care Ontario, Toronto

Tom Hudson

McGill University and Génome Québec

Innovation Centre, Montreal

October 2004 – December 2007

$9.6 million

Segmental Duplications in

Neurodevelopmental, Neurological

and Behavioural Disorders

Stephen Scherer


Xavier Estivill

Centro de Regulació Genòmica,

Barcelona

April 2004 – September 2007

$5.2 million

Genetic Determinants of Human

Health and Disease

Katherine Siminovitch




$11.0 million

Bridging the Emerging

Genomics Divide




$2.8 million

Mapping and Isolation of Genes

Influencing Severity of Disease in

Cystic Fibrosis

Peter Durie, Lap-Chee Tsui



$6.4 million

Functional Genomics of

Type 1 Diabetes

Jayne Danska



$8.5 million

The Stem Cell Genomics Project

Michael Rudnicki

Ottawa Health Research Institute

July 2002 – March 2006

$11.1 million

Genetic Determinants of Human

Health and Disease – Annotation of

Chromosome 7

Stephen Scherer



$1.8 million

Canadian Program on Genomics and

Global Health




$6.2 million

Functional Genomics and Proteomics

of Model Organisms

Janet Rossant, Anthony Pawson




Functional Genomics of Arabidopsis

John Coleman


July 2002 – September 2005

$1.8 million

Fiber Optic Nucleic Acid (FONA)

Biosensor-based Gene Profiling:

Proof of Principle by Screening

for Drug Leads for Orphan

Neurodegenerative Disorders

and SNP Analysis

Alex MacKenzie

Children’s Hospital of Eastern Ontario,

Ottawa

Paul Piunno, Ulrich Krull

University of Toronto at Mississauga

July 2002 – June 2005

$2.8 million

2 6

Viral Proteomics

Lori Frappier, Christian Burks

Affinium Pharmaceuticals, Toronto

July 2002 – December 2004

$6.3 million

ENVIRONMENT

Environmental Barcoding through

Massively Parallelized Sequencing

Paul Hebert



$1.8 million

Canadian Barcode of Life Network

Paul Hebert



$11.0 million

Genomic Analysis of Soil

Microorganisms

Turlough Finan, Brian Golding

McMaster University, Hamilton


$5.9 million

Genomics of the Spruce Budworm

and its Viral Pathogens

Arthur Retnakaran, Basil Arif

Great Lakes Forestry Centre – NRC,

Sault Ste. Marie


$4.6 million

TECHNOLOGY DEVELOPMENT AND INFORMATICS


(SGC) – Phase II

Aled Edwards



Karolinska Institute, Stockholm (Sweden)

July 2007 – June 2011

$118.5 million

Automated Three-dimensional

Phenotyping of Mouse Embryos

Mark Henkelman


April 2008 – September 2010

$1.4 million

Software Tools to Simplify Gene

Function Prediction

Gary Bader, Quaid Morris



$1.9 million

Multiplexed MicroRNA Detection on

an Electronic Chip

Shana Kelley, Ted Sargent



$0.9 million

Massively Multiparametric Flow

Cytometer Analyzer

Scott Tanner



$2.8 million

Integrative Biology

Brenda Andrews


January 2006 – December 2009

$26.8 million

Mass Spectrometer-based Flow

Cytometer, Methods and Applications

John Dick



$7.8 million


(SGC) – Phase I

Aled Edwards



Karolinska Institute, Stockholm (Sweden)

July 2003 – June 2007

$105.0 million

Proteomics and Functional Genomics

– An Integrated Approach

Brenda Andrews, Cheryl Arrowsmith


July 2002 – March 2006

$15.0 million

2 7

2 8

Dollar amounts are total approved project costs as of May 2014.

Functional Genomics and Proteomics

of Model Organisms

Jack Greenblatt, Andrew Spence,

Brenda Andrews



$26.5 million

Development and Applications of

Functional Genomics Technologies

James Woodgett



$8.8 million

The Biomolecular Interaction

Network Database (BIND)

Christopher Hogue




$23.1 million

Genomic Resource Core Facility

Stephen Scherer, Lap-Chee Tsui



$18.0 million

Proteomics Technology Core Facility

(PTCF)

Jack Greenblatt


Gilles Lajoie



$8.6 million

Board of Directors

Brian Underdown (Chair)

Managing Director,

Technology Investing

Lumira Capital

Jack Gauldie

Professor and Chairman, Department of

Pathology and Molecular Medicine

McMaster University

Stephen L. Cummings

CFO and Financial Consultant

Jay A. Lefton

Partner

Borden Ladner Gervais

Paul Lucas

Former President and CEO

GlaxoSmithKline

John P. Molloy

President and CEO, PARTEQ

Innovations

Queen’s University

Caroline Popper

Founder and President

Popper and Company LLC.

Mark Poznansky

President and CEO

Ontario Genomics Institute

Tom Rand

Managing Partner

MaRS Cleantech Fund I, LP

Senior Advisor

MaRS Cleantech Venture Group

Robert Roberts

President, CEO and Chief

Scientific Officer

University of Ottawa Heart Institute

Bonnie Schmidt

President

Let’s Talk Science

Niclas Stiernholm

President and CEO

Stem Cell Therapeutics

Cal Stiller

Chair and CEO

Stilco

Scott Tanner

Chief Technology Officer

Fluidigm Canada

(formerly DVS Sciences)

2 9

As of May 2014.

Mark Poznansky

President & CEO

Mahima Agochiya

Manager, Business Development and

Research

Farzian Aminuddin

Business Analyst

Christine Beyaert

Manager, Corporate Communications

Kathryn Deuchars

Senior Manager, Business Development

and Research

Director, Ontario Personalized Medicine

Network

Kim Flock

Manager, Research and

Business Development

Christy Hockley

Project Coordinator

Sugy Kodeeswaran


and Research

Les Kondejewski

Director, Research Programs

Dennis McCormac

Director, Genomics Services and

Technology Advisor

Tina McDivitt

Senior Strategist

Kajal Palan

Director, Finance

Helen Petropoulos


and Research

Shobha Ramsubir


and Research

Christine Scaramuzzo

Director of Operations

Alison Symington

Vice President, Research and

Corporate Development

Rhonda Tannenbaum

Vice President, Business Development

Staff

As of May 2014.

3 0

genomics is changing everything

Documents